EPCAM and ovarian cancer: The CTCs marked as CD45-/HE4+EpCAM+cytokeratin+vimentin+ cells were increased in ovarian cancer patients and showed positivity in 49% of patients with a sensitivity of 73%, higher than that for CA125 [190].